Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 35 Issue 1
. 
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2017  >  35(1): 82-86

SHEN Liru, LI Ruihong, WANG Tailiang. Simultaneous determination of peimine and peiminine in Xiaoer Baotaikang granules by HPLC-ELSD[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 351-353. doi: 10.3969/j.issn.1006-0111.2016.04.017
Citation: JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2017.01.021
  • 1.

    The 71571 Unit of PLA, Yantai 265500, China

  • 2.

    The Gynecology & Obstetrics of Yuhuangding Hospital, Yantai 265000, China

  • Received Date: 2016-03-07
  • Rev Recd Date: 2016-07-18
  • Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC). Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group[RR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456). Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.
  • [1] Cheng S, Evans WK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer:a systematic review and practice guideline[J]. J Thorac Oncol, 2007,2(4):348-354.
    [2] Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC)[J]. Cancer Treat Rev, 2011,37(2):143-150.
    [3] Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA, 2000,283(15):2008-2012.
    [4] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010,25(9):603-605.
    [5] O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase Ⅱ study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer-EORTC 08062[J]. Eur J Cancer, 2011,47(15):2322-2330.
    [6] Satouchi M, Kotani Y, Shibata T, et al. Phase Ⅲ study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer:JCOG 0509[J]. J Clin Oncol, 2014,32(12):1262-1268.
    [7] Sekine I, Okamoto H, Horai T, et al. A randomized phase Ⅲ study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer[J]. Clin Lung Cancer, 2014,15(2):96-102.
    [8] Wakuda K, Kenmotsu H, Naito T, et al. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer[J]. Am J Clin Oncol, 2015,38(1):28-32.
    [9] Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase Ⅱ trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer:North Japan Lung Cancer Study Group Trial 0402[J]. J Clin Oncol, 2008,26(33):5401-5406.
    [10] Inoue A, Sugawara S, Maemondo M, et al. Randomized phase Ⅱ trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer:North Japan Lung Cancer Study Group trial 0702[J]. Lung Cancer, 2015, 89(1):61-65.
    [11] Jotte R, Conkling P, Reynolds C, et al. Randomized phase Ⅱ trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy[J]. J Clin Oncol, 2011,29(3):287-293.
    [12] von Pawel J, Jotte R, Spigel DR, et al. Randomized phase Ⅲ trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer[J]. J Clin Oncol, 2014,32(35):4012-4019.
    [13] Tani N, Yabuki M, Komuro S, et al. Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride[J]. Xenobiotica, 2005,35(12):1121-1133.
  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0400.511.522.5Highcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 87.2 %FULLTEXT: 87.2 %META: 11.0 %META: 11.0 %PDF: 1.8 %PDF: 1.8 %FULLTEXTMETAPDFHighcharts.com
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 25.0 %其他: 25.0 %其他: 0.3 %其他: 0.3 %Canada: 0.1 %Canada: 0.1 %China: 1.3 %China: 1.3 %Neptune City: 0.3 %Neptune City: 0.3 %United States: 0.5 %United States: 0.5 %[]: 0.8 %[]: 0.8 %上海: 3.4 %上海: 3.4 %中卫: 0.1 %中卫: 0.1 %临汾: 0.3 %临汾: 0.3 %临沂: 0.5 %临沂: 0.5 %兰州: 0.3 %兰州: 0.3 %北京: 13.8 %北京: 13.8 %南宁: 0.4 %南宁: 0.4 %南昌: 0.1 %南昌: 0.1 %厦门: 0.1 %厦门: 0.1 %台州: 0.1 %台州: 0.1 %呼和浩特: 0.1 %呼和浩特: 0.1 %哈尔滨: 0.3 %哈尔滨: 0.3 %宁波: 0.3 %宁波: 0.3 %巴音郭楞: 0.1 %巴音郭楞: 0.1 %广安: 0.1 %广安: 0.1 %广州: 0.3 %广州: 0.3 %张家口: 0.4 %张家口: 0.4 %徐州: 0.1 %徐州: 0.1 %恩施: 0.1 %恩施: 0.1 %成都: 0.1 %成都: 0.1 %昆明: 0.1 %昆明: 0.1 %普洱: 0.1 %普洱: 0.1 %杭州: 1.2 %杭州: 1.2 %枣庄: 0.3 %枣庄: 0.3 %桂林: 0.3 %桂林: 0.3 %梅州: 0.1 %梅州: 0.1 %榆林: 0.1 %榆林: 0.1 %武汉: 0.3 %武汉: 0.3 %沈阳: 0.1 %沈阳: 0.1 %泰安: 0.1 %泰安: 0.1 %济南: 0.1 %济南: 0.1 %济宁: 0.1 %济宁: 0.1 %深圳: 0.3 %深圳: 0.3 %漯河: 0.1 %漯河: 0.1 %百色: 0.1 %百色: 0.1 %盐城: 0.3 %盐城: 0.3 %石家庄: 0.9 %石家庄: 0.9 %芒廷维尤: 26.9 %芒廷维尤: 26.9 %芝加哥: 0.1 %芝加哥: 0.1 %衢州: 0.1 %衢州: 0.1 %西宁: 14.5 %西宁: 14.5 %西安: 0.1 %西安: 0.1 %达尔斯: 0.1 %达尔斯: 0.1 %运城: 0.5 %运城: 0.5 %遵义: 0.1 %遵义: 0.1 %郑州: 0.9 %郑州: 0.9 %重庆: 0.3 %重庆: 0.3 %长沙: 0.9 %长沙: 0.9 %长治: 0.1 %长治: 0.1 %防城港: 0.1 %防城港: 0.1 %阳泉: 0.1 %阳泉: 0.1 %青岛: 0.1 %青岛: 0.1 %黄冈: 0.8 %黄冈: 0.8 %黔东南: 0.1 %黔东南: 0.1 %其他其他CanadaChinaNeptune CityUnited States[]上海中卫临汾临沂兰州北京南宁南昌厦门台州呼和浩特哈尔滨宁波巴音郭楞广安广州张家口徐州恩施成都昆明普洱杭州枣庄桂林梅州榆林武汉沈阳泰安济南济宁深圳漯河百色盐城石家庄芒廷维尤芝加哥衢州西宁西安达尔斯运城遵义郑州重庆长沙长治防城港阳泉青岛黄冈黔东南Highcharts.com

  • Cited by

    Periodical cited type(4)

    1. 杨雅婷，吕晓君，张菊，徐小玲，何开勇，沈佳特. 氟马西尼原料药中细菌内毒素检查. 医药导报. 2024(09): 1470-1476 .
    2. 邝昆合，郑德志，江进红，李显立. 氟马西尼用于静吸复合全麻术后催醒的临床效果观察. 中国实用医药. 2023(09): 116-119 .
    3. 张宗鹏，王治国，石庆学，张国旭，霍花. 不同比活度~(11)C-氟马西尼体内代谢的差异分析. 药学实践杂志. 2020(04): 318-321 .
    4. 侯成，卢光照，鲁莹，董腾腾，邹豪. 军事人员对抗睡眠剥夺策略的研究进展. 第二军医大学学报. 2020(09): 1012-1020 .

    Other cited types(1)

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3516) PDF downloads(868) Cited by(5)

Related
Proportional views

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2017.01.021
  • 1. The 71571 Unit of PLA, Yantai 265500, China
  • 2. The Gynecology & Obstetrics of Yuhuangding Hospital, Yantai 265000, China
  • Received Date: 2016-03-07
  • Rev Recd Date: 2016-07-18

Abstract: Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC). Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group[RR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456). Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.

SHEN Liru, LI Ruihong, WANG Tailiang. Simultaneous determination of peimine and peiminine in Xiaoer Baotaikang granules by HPLC-ELSD[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(4): 351-353. doi: 10.3969/j.issn.1006-0111.2016.04.017
Citation: JIN Haichao, XING Fangkai, CHEN Tao, LV Wenling. Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(1): 82-86. doi: 10.3969/j.issn.1006-0111.2017.01.021
shu

    HTML

Reference (13)

Catalog

  • HTML

版权所有：《药学实践与服务》编辑委员会

Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

Tel: （021）81871324,81871397 E-mail: yxsjzzs@163.com

网站备案号 沪ICP备05003363号-1

Supported by: Beijing Renhe Information Technology Co., Ltd.  

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return